199 related articles for article (PubMed ID: 27486136)
1. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
2. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
3. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
[No Abstract] [Full Text] [Related]
4. A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.
Pisani A; Visciano B; Russo R; Mozzillo GR; Porto C; De Maggio I; Russo R; Pontarelli G; Villani GR; Cianciaruso B; Di Natale P
J Nephrol; 2012; 25(4):582-5. PubMed ID: 22307442
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
6. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
7. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
8. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
9. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
10. Fabry disease: Review and experience during newborn screening.
Hsu TR; Niu DM
Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
[TBL] [Abstract][Full Text] [Related]
11. The Changing Landscape of Fabry Disease.
Svarstad E; Marti HP
Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
[No Abstract] [Full Text] [Related]
12. Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).
Suzuki K; Miura N; Kitagawa W; Suzuki S; Komatsuda A; Nishikawa K; Watanabe D; Imai H
Clin Exp Nephrol; 2011 Dec; 15(6):916-20. PubMed ID: 21755431
[TBL] [Abstract][Full Text] [Related]
13. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: is there a role for enzyme replacement therapy?
Mehta AB
J Intern Med; 2013 Oct; 274(4):329-30. PubMed ID: 23662843
[No Abstract] [Full Text] [Related]
15. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
Banikazemi M; Desnick RJ
Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
[No Abstract] [Full Text] [Related]
16. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak CE; Linthorst GE
Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
[No Abstract] [Full Text] [Related]
17. Fabry disease: dose matters.
Warnock DG; Mauer M
J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
[No Abstract] [Full Text] [Related]
18. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
19. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
20. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
Roganović J
Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
[No Abstract] [Full Text] [Related]
[Next] [New Search]
